medonline
Posts for keyword:

Pembrolizumab

CMP-001Published on: 18 Apr 2018
Mohammed Milhem on the combination of CMP-001 + Pembro
Mohammed Milhem presents preliminary data on the combination of the TLR9 agonist CMP-001 and pembrolizumab in patients with metastatic melanoma resistant to anti-PD-1.
CMP-001Published on: 17 Apr 2018
Combination CMP-001 + Pembro in anti-PD-1-resistant melanoma
TLR9 agonist CMP-001-pembrolizumab combination shows early efficacy in patients with metastatic melanoma resistant to anti-PD-1.
NSCLCPublished on: 17 Apr 2018
Leena Gandhi on the results of KEYNOTE-189
In the study, the combination of chemotherapy with pembrolizumab performed significantly better in terms of ORR, PFS and OS.
MelanomPublished on: 16 Apr 2018
Alexander Eggermont presents the results of KEYNOTE-054
Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, talks about the key findings of the KEYNOTE-054 trial and highlights pembrolizumab's high therapeutic index.
AACR 2018Published on: 15 Apr 2018
Pembrolizumab reduced the risk for recurrence of stage 3 melanoma
In the KEYNOTE-054/EORTC 1325 MG-trial, patients randomized to pembrolizumab were 43 percent less likely to have recurrence.
MelanomPublished on: 12 Apr 2018
Pembrolizumab in adjuvant treatment of advanced melanoma
The results of the placebo controlled double blind phase III study Keynote 054 will be presented at the AACR annual meeting.
NivolumabPublished on: 12 Apr 2018
Checkpoint inhibitors and platinum as first line treatment for NSCLC
Combinations of immune checkpoint inhibitors and chemotherapy show promising results. Results of the the KEYNOE 189 study will be presented at the AACR.